Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peposertib + avelumab
- Development stage
- Phase 2
- Lead developer
- Merck KGaA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Peposertib + avelumab is a combination of two investigational agents studied for advanced solid tumors. Peposertib (M3814) is a potent, selective small molecule inhibitor of DNA-dependent protein kinase (DNA-PK), a critical enzyme in DNA double-strand break repair by nonhomologous end joining (NHEJ). Avelumab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. The combination was evaluated in a phase I trial, demonstrating tolerability up to defined dose levels, but with limited antitumor activity in a heavily pretreated population. Primarily developed and manufactured by Merck and Pfizer (avelumab), the combination is studied as an antineoplastic, immunotherapy regimen seeking to synergize DNA damage and adaptive immune response inhibition[1][3].
- Brand names
- Bavencio (avelumab)
- Other names
- M3814 + avelumabDNA-PK inhibitor + anti-PD-L1 antibody
02
Targets
DNA-PK (DNA-dependent protein kinase)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on peposertib + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peposertib + avelumab.